Cipher Pharmaceuticals Inc. Logo

Cipher Pharmaceuticals Inc.

CPHRF

(2.5)
Stock Price

10,15 USD

29.38% ROA

17.93% ROE

13.17x PER

Market Cap.

316.022.915,00 USD

0.33% DER

0% Yield

59.92% NPM

Cipher Pharmaceuticals Inc. Stock Analysis

Cipher Pharmaceuticals Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cipher Pharmaceuticals Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (45.6%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 DER

The stock has a minimal amount of debt (1%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 PBV

The stock's PBV ratio (1.41x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

5 Assets Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

6 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

7 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (5), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

8 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

10 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Cipher Pharmaceuticals Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cipher Pharmaceuticals Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Cipher Pharmaceuticals Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cipher Pharmaceuticals Inc. Revenue
Year Revenue Growth
2004 25.417.172
2005 646.633 -3830.7%
2006 778.997 16.99%
2007 543.269 -43.39%
2008 1.267.871 57.15%
2009 3.036.004 58.24%
2010 5.384.138 43.61%
2011 3.495.592 -54.03%
2012 8.501.955 58.88%
2013 25.367.919 66.49%
2014 8.258.995 -207.16%
2015 34.409.000 76%
2016 40.740.000 15.54%
2017 40.320.000 -1.04%
2018 22.749.000 -77.24%
2019 22.451.000 -1.33%
2020 21.607.000 -3.91%
2021 21.943.000 1.53%
2022 20.675.000 -6.13%
2023 24.272.000 14.82%
2023 21.550.086 -12.63%
2024 21.211.624 -1.6%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cipher Pharmaceuticals Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2004 10.360.690
2005 12.134.492 14.62%
2006 7.264.927 -67.03%
2007 2.285.166 -217.92%
2008 1.070.665 -113.43%
2009 912.997 -17.27%
2010 742.881 -22.9%
2011 2.159.647 65.6%
2012 1.524.883 -41.63%
2013 1.304.507 -16.89%
2014 1.056.975 -23.42%
2015 2.143.000 50.68%
2016 561.000 -282%
2017 394.000 -42.39%
2018 561.000 29.77%
2019 396.000 -41.67%
2020 129.000 -206.98%
2021 88.000 -46.59%
2022 98.000 10.2%
2023 40.000 -145%
2023 141.549 71.74%
2024 188.000 24.71%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cipher Pharmaceuticals Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 3.912.582 100%
2014 5.678.019 31.09%
2015 16.594.000 65.78%
2016 23.739.000 30.1%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 4.400.000 100%
2023 6.760.000 34.91%
2023 5.393.000 -25.35%
2024 5.080.000 -6.16%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cipher Pharmaceuticals Inc. EBITDA
Year EBITDA Growth
2004 -5.201.557
2005 -14.183.744 63.33%
2006 -9.929.650 -42.84%
2007 -6.808.038 -45.85%
2008 -2.732.128 -149.18%
2009 -1.937.733 -41%
2010 746.880 359.44%
2011 -1.748.286 142.72%
2012 3.451.846 150.65%
2013 18.109.075 80.94%
2014 -3.526.875 613.46%
2015 4.768.000 173.97%
2016 4.348.000 -9.66%
2017 26.216.000 83.41%
2018 6.158.000 -325.72%
2019 12.868.000 52.14%
2020 13.401.000 3.98%
2021 12.522.000 -7.02%
2022 12.074.000 -3.71%
2023 14.904.000 18.99%
2023 11.466.498 -29.98%
2024 10.385.848 -10.41%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cipher Pharmaceuticals Inc. Gross Profit
Year Gross Profit Growth
2004 25.417.172
2005 646.633 -3830.7%
2006 778.997 16.99%
2007 370.595 -110.2%
2008 1.267.871 70.77%
2009 3.036.004 58.24%
2010 5.384.138 43.61%
2011 3.495.592 -54.03%
2012 6.980.009 49.92%
2013 25.234.557 72.34%
2014 7.229.394 -249.05%
2015 31.884.000 77.33%
2016 36.153.000 11.81%
2017 38.417.000 5.89%
2018 20.437.000 -87.98%
2019 19.545.000 -4.56%
2020 18.550.000 -5.36%
2021 18.259.000 -1.59%
2022 16.683.000 -9.45%
2023 19.968.000 16.45%
2023 16.156.964 -23.59%
2024 15.620.780 -3.43%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cipher Pharmaceuticals Inc. Net Profit
Year Net Profit Growth
2004 -9.932.287
2005 -7.324.780 -35.6%
2006 -10.349.176 29.22%
2007 -6.508.129 -59.02%
2008 -2.654.067 -145.21%
2009 -2.592.876 -2.36%
2010 55.991 4730.88%
2011 -2.263.467 102.47%
2012 2.557.220 188.51%
2013 23.448.256 89.09%
2014 -4.824.933 585.98%
2015 1.769.000 372.75%
2016 -39.149.000 104.52%
2017 4.281.000 1014.48%
2018 543.000 -688.4%
2019 3.242.000 83.25%
2020 4.549.000 28.73%
2021 7.758.000 41.36%
2022 26.636.000 70.87%
2023 28.124.000 5.29%
2023 20.383.000 -37.98%
2024 11.980.000 -70.14%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cipher Pharmaceuticals Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 1 0%
2014 0 0%
2015 0 0%
2016 -1 100%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 1 100%
2023 1 0%
2023 1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cipher Pharmaceuticals Inc. Free Cashflow
Year Free Cashflow Growth
2004 -16.696.891
2005 -12.028.586 -38.81%
2006 -11.536.548 -4.27%
2007 -4.156.316 -177.57%
2008 -887.428 -368.36%
2009 -1.420.113 37.51%
2010 506.918 380.15%
2011 -810.970 162.51%
2012 6.103.555 113.29%
2013 7.006.207 12.88%
2014 -4.307.320 262.66%
2015 199.000 2264.48%
2016 10.837.000 98.16%
2017 19.728.000 45.07%
2018 4.656.000 -323.71%
2019 7.549.000 38.32%
2020 10.931.000 30.94%
2021 13.814.000 20.87%
2022 10.494.000 -31.64%
2023 5.972.000 -75.72%
2023 16.145.762 63.01%
2024 6.186.477 -160.98%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cipher Pharmaceuticals Inc. Operating Cashflow
Year Operating Cashflow Growth
2004 -16.257.674
2005 -12.001.894 -35.46%
2006 -11.268.016 -6.51%
2007 -3.995.759 -182%
2008 -879.211 -354.47%
2009 -1.295.960 32.16%
2010 1.242.801 204.28%
2011 -799.216 255.5%
2012 6.898.666 111.59%
2013 7.020.295 1.73%
2014 -2.529.654 377.52%
2015 7.764.000 132.58%
2016 11.469.000 32.3%
2017 19.930.000 42.45%
2018 11.284.000 -76.62%
2019 8.860.000 -27.36%
2020 11.691.000 24.22%
2021 13.814.000 15.37%
2022 10.575.000 -30.63%
2023 5.972.000 -77.08%
2023 16.292.402 63.34%
2024 6.197.440 -162.89%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cipher Pharmaceuticals Inc. Capital Expenditure
Year Capital Expenditure Growth
2004 439.217
2005 26.692 -1545.56%
2006 268.531 90.06%
2007 160.557 -67.25%
2008 8.217 -1854.2%
2009 124.152 93.38%
2010 735.882 83.13%
2011 11.753 -6161.23%
2012 795.111 98.52%
2013 14.088 -5544.28%
2014 1.777.667 99.21%
2015 7.565.000 76.5%
2016 632.000 -1096.99%
2017 202.000 -212.87%
2018 6.628.000 96.95%
2019 1.311.000 -405.57%
2020 760.000 -72.5%
2021 0 0%
2022 81.000 100%
2023 0 0%
2023 146.640 100%
2024 10.963 -1237.59%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cipher Pharmaceuticals Inc. Equity
Year Equity Growth
2004 25.358.943
2005 19.162.218 -32.34%
2006 18.413.692 -4.07%
2007 15.830.556 -16.32%
2008 10.705.012 -47.88%
2009 10.474.644 -2.2%
2010 11.472.164 8.7%
2011 9.304.603 -23.3%
2012 12.470.472 25.39%
2013 36.400.349 65.74%
2014 6.617.860 -450.03%
2015 54.257.000 87.8%
2016 18.014.000 -201.19%
2017 22.936.000 21.46%
2018 24.759.000 7.36%
2019 28.011.000 11.61%
2020 32.642.000 14.19%
2021 38.897.000 16.08%
2022 64.080.000 39.3%
2023 80.108.035 20.01%
2023 77.548.000 -3.3%
2024 88.782.977 12.65%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cipher Pharmaceuticals Inc. Assets
Year Assets Growth
2004 32.361.455
2005 22.139.659 -46.17%
2006 19.309.368 -14.66%
2007 18.901.343 -2.16%
2008 13.456.861 -40.46%
2009 14.156.241 4.94%
2010 16.170.412 12.46%
2011 14.357.492 -12.63%
2012 22.069.097 34.94%
2013 52.170.891 57.7%
2014 11.135.269 -368.52%
2015 109.646.000 89.84%
2016 77.405.000 -41.65%
2017 63.130.000 -22.61%
2018 55.686.000 -13.37%
2019 46.455.000 -19.87%
2020 44.276.000 -4.92%
2021 51.651.000 14.28%
2022 73.776.000 29.99%
2023 85.590.839 13.8%
2023 90.529.000 5.45%
2024 93.896.227 3.59%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cipher Pharmaceuticals Inc. Liabilities
Year Liabilities Growth
2004 7.002.512
2005 2.977.441 -135.19%
2006 895.676 -232.42%
2007 3.070.786 70.83%
2008 2.751.848 -11.59%
2009 3.681.596 25.25%
2010 4.698.248 21.64%
2011 5.052.889 7.02%
2012 9.598.624 47.36%
2013 15.770.541 39.14%
2014 4.517.408 -249.11%
2015 55.389.000 91.84%
2016 59.391.000 6.74%
2017 40.194.000 -47.76%
2018 30.927.000 -29.96%
2019 18.444.000 -67.68%
2020 11.634.000 -58.54%
2021 12.754.000 8.78%
2022 9.696.000 -31.54%
2023 5.482.804 -76.84%
2023 12.981.000 57.76%
2024 5.113.250 -153.87%

Cipher Pharmaceuticals Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.92
Net Income per Share
0.94
Price to Earning Ratio
13.17x
Price To Sales Ratio
14.19x
POCF Ratio
17.43
PFCF Ratio
18.68
Price to Book Ratio
3.35
EV to Sales
12.05
EV Over EBITDA
21.7
EV to Operating CashFlow
15.71
EV to FreeCashFlow
15.86
Earnings Yield
0.08
FreeCashFlow Yield
0.05
Market Cap
0,32 Bil.
Enterprise Value
0,27 Bil.
Graham Number
8.81
Graham NetNet
1.96

Income Statement Metrics

Net Income per Share
0.94
Income Quality
0.75
ROE
0.27
Return On Assets
0.1
Return On Capital Employed
0.08
Net Income per EBT
1.67
EBT Per Ebit
0.84
Ebit per Revenue
0.43
Effective Tax Rate
-0.67

Margins

Sales, General, & Administrative to Revenue
0.25
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.81
Operating Profit Margin
0.43
Pretax Profit Margin
0.36
Net Profit Margin
0.6

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.71
Free CashFlow per Share
0.7
Capex to Operating CashFlow
0.01
Capex to Revenue
0.01
Capex to Depreciation
0.14
Return on Invested Capital
0.23
Return on Tangible Assets
0.29
Days Sales Outstanding
61.89
Days Payables Outstanding
309.87
Days of Inventory on Hand
208.45
Receivables Turnover
5.9
Payables Turnover
1.18
Inventory Turnover
1.75
Capex per Share
0.01

Balance Sheet

Cash per Share
1,99
Book Value per Share
3,68
Tangible Book Value per Share
2.98
Shareholders Equity per Share
3.68
Interest Debt per Share
0.01
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-3.86
Current Ratio
11.18
Tangible Asset Value
0,07 Bil.
Net Current Asset Value
0,05 Bil.
Invested Capital
67356605
Working Capital
0,05 Bil.
Intangibles to Total Assets
0.18
Average Receivables
0,01 Bil.
Average Payables
0,01 Bil.
Average Inventory
2831360
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cipher Pharmaceuticals Inc. Dividends
Year Dividends Growth

Cipher Pharmaceuticals Inc. Profile

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.

CEO
Mr. Craig J. Mull
Employee
6
Address
209 Oak Park Boulevard
Oakville, L6H 0M2

Cipher Pharmaceuticals Inc. Executives & BODs

Cipher Pharmaceuticals Inc. Executives & BODs
# Name Age
1 Dr. Hamed Ghanei
Chief Business Officer
70
2 Mr. Craig J. Mull
Interim Chief Executive Officer & Chairman of the Board
70
3 Mr. Emilio Presti
Director of Sales & Marketing
70
4 Mr. Bryan Jacobs
Chief Financial Officer
70

Cipher Pharmaceuticals Inc. Competitors